EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

India Pushes for Pharma Market Access in Argentina and Brazil - What This Means for Buyers For buyers of Indian generic medicines, the South America push signals several practical developments: More competitive pricing — as Indian manufacturers gain access to larger regional markets, economies of scale could drive down prices for commonly prescribed generics, including cardiovascular drugs, antibiotics, and diabetes medications. Expanded product availability — Indian […]
CBN and PHARMEXCIL Sign MoU on Controlled Substances Exports - On August 25, 2026, India’s Central Bureau of Narcotics (CBN) and the Pharmacy Export Promotion Council of India (PHARMEXCIL) signed a Memorandum of Understanding (MoU) to strengthen regulatory oversight of controlled substances in pharmaceutical exports. The agreement, reported by ANI News, The Economic Times, Express Pharma, and multiple other outlets, aims to prevent the diversion […]
CDSCO Flags 280 Drug Batches Substandard in August 2026 Sweep - India’s Central Drugs Standard Control Organisation (CDSCO) has flagged approximately 280 drug batches as Not of Standard Quality (NSQ) in its latest quality surveillance sweep, according to reports in The Economic Times (August 21, 2026). The finding underscores the regulator’s ongoing post-market quality monitoring efforts across India’s pharmaceutical manufacturing landscape. 📊 What the CDSCO Quality […]
CDSCO Waives Phase 3 Trials for Generic Lenacapavir HIV Drug - The Central Drugs Standard Control Organisation (CDSCO) has waived the requirement for local Phase 3 clinical trials for generic versions of lenacapavir, a breakthrough HIV prevention drug, moving India significantly closer to affordable long-acting HIV pre-exposure prophylaxis (PrEP). As reported by ThePrint on August 25, 2026, this regulatory waiver is expected to accelerate the availability […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us